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Factor V Leiden mutation, prothrombin gene mutation, and deficiencies
in coagulation inhibitors associated with Budd-Chiari syndrome
and portal vein thrombosis: results of a case-control study
HarryL A Janssen, Johan R Memardi, Frank P Vleggaar, Stan H M van Uum, Ehzabeth B Haagsma, Felix J M van der Meer,
Jan van Hattum, Robert A F M Chamuleau, Rob P Adang, Jan P Vandenbroucke, Bart van Hoek, and Fnts R Rosendaal
In a collaborative multicenter case-con-
trol study, we investigated the effect of
factor V Leiden mutation, prothrombin
gene mutation, and inherited deficiencies
of protein C, protein S, and antithrombin
on the risk of Budd-Chiari syndrome
(BCS) and portal vein thrombosis (PVT).
We compared 43 BCS patients and 92
PVT patients with 474 population-based
controls. The relative risk of BCS was
11.3 (95% Cl 4.8-26.5) for individuals with
factor V Leiden mutation, 2.1(95% Cl 0.4-
9.6) for those with prothrombin gene mu-
tation, and 6.8 (95% Cl 1.9-24.4) forthose
Introduction
with protein C deficiency. The relative risk
of PVT was 2.7 (95% Cl 1.1-6.9) for indi-
viduals with factor V Leiden mutation, 1.4
(95% Cl 0.4-5.2) for those with prothrom-
bin gene mutation, and 4.6 (95% Cl 1.5-
14.1) for those with protein C deficiency.
The relative risk of BCS or PVT was not
increased in the presence of inherited
protein S or antithrombin deficiency. Con-
currence of either acquired or inherited
thrombotic risk factors was observed in
26% of the BCS patients and 37% of the
PVT patients. We conclude that factor V
Leiden mutation and hereditary protein C
deficiency appear to be important risk
factors for BCS and PVT. Although the
prevalence of the prothrombin gene muta-
tion was increased, it was not found to be
a significant risk factor for BCS and PVT.
The coexistence of thrombogenic risk
factors in many patients indicates that
BCS and PVT can be the result of a
combined effect of different pathogenetic
mechanisms (Blood 2000;96:2364-2368)
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Budd-Chian syndrome (BCS) represents occlusion of hepatic
outflow either at the level of the hepatic veins or inferior vena
cava' Chnically, the disease is charactenzed by hepatomegaly,
mamfestations of portal hypertension, and sometimes rapidly
detenorating hver function 2 Portal vein thrombosis (PVT) often
occurs in conditions leadmg to decreased portal flow and also
becomes manifest by Symptoms of portal hypertension 3 Both BCS
and PVT have been hnked to several hypercoagulable states,
pnmanly myeloproliferative disorders 4 However, most studies on
the pathogenesis of BCS and PVT contam few patients or are
hampered by the lack of complete testmg for thrombophiha and
absence of a well-documented control group
Resistance to acnvated protein C due to factor V Leiden mutation is
to date the most frequent cause of hereditary thrombophiha5 6 Its
prevalence in the general white populahon is approximately 5%, but the
relative nsk of BCS and PVT for subjects carrying factor V Leiden
mutation is uncertain In a recent study, factor V Leiden appeared to be
present in about one fourth of patients with BCS, whereas its occurrence
in patients with PVT was negligible7
Carners of the prothrombin gene mutation, which results from
guanme to adenine transition at nucleotide position 20210 in the 3'
untranslated region of the gene, exhibit increased plasma levels of
prothrombin and may therefore be at increased nsk for venous
thromboembolisms 8 This mutation, also referred to äs prothrombin
20210 A vanant, has recently been recognized äs a nsk factor for a
selected group of patients with idiopathic PVT9 With regard to
BCS, the impact of the prothrombin gene mutation is uncertain 10
For both BCS and PVT, the importance of several other hypercoag-
ulable states, such äs mhented deficiencies of the coagulation
inhibitors protein C, protein S, and antithrombin, is also unknown
because their association with BCS and PVT is based solely on
anecdotal reports n·12
We mitiated a large multicenter population-based case-control
study to estabhsh the influence of factor V Leiden mutation,
prothrombin gene mutation, protein C deficiency, protein S defi-
ciency, or antithrombin deficiency on the risk of BCS and PVT
Patients and methods
Patients were selected by means of a search in the computenzed
hospital registration Systems (ZIS) of 7 academic hospitals in The
Netherlands The hospitals were located in Leiden, Groningen,
Rotterdam, Utrecht, Nijmegen, Amsterdam, and Maastricht All
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patients registered with the diagnosis of BCS or PVT between
January 1984 and July 1997 were identified Diagnostic cntena for
BCS and PVT were partial or complete obstruction of hepatic
outflow or the portal vein, respectively, äs documented by appropn-
ate radiographic abdominal imaging (le, Doppier ultrasonography,
computed tomography, magnetic resonance imaging, venography)
or laparotomy We excluded patients with veno-occlusive disease,
patients with hepatic outflow obstruction caused by congestive
heart failure, and patients who were younger than 15 years of age in
July 1997 For all identified patients (BCS, n = 76, PVT, n = 214)
a standardized questionnaire, askmg for specific chmcal Informa-
tion to confirm the diagnosis of PVT and BCS, was completed with
data obtamed from the medical charts by local mvestigators under
close supervision of one member of our team (H L A J ) Twenty-
five patients with BCS and 100 with PVT had died before July
1997 Patients alive were asked to visit the hospital in which they
were registered for blood samphng, at the same time enabling
mvestigators to complete the questionnaire with Information on
previous thrombotic events, famihal thrombosis, acquired nsk
factors of thrombosis, and the use of anticoagulants at the time of
venipuncture Eight patients could not be traced, 14 were unwilling
to participate, and 5 were registered in 2 hospitals, m 3 cases
msufficient matenal for DNA extraction was obtamed Forty-three
patients with BCS and 92 patients with PVT were enrolled m the
study and underwent a füll screenmg for thrombogemc disorders
Five patients had both BCS and PVT These patients were mcluded
in the analyses of both diseases The population-based control
group consisted of 474 healthy individuals who had no history of
venous thromboembohsm, had not used coumann derivatives for at
least 3 months before blood samphng, and had no myeloprohfera-
tive or mahgnant disease (LETS study control population6) Age,
sex, and ethnic descent of patients and the controls wert similar
More than 95% of patients and controls were of Caucasian ongm
The study was approved by the ethical committee of each
participatmg hospital and the participants gave their mformed
consent before entenng the study
Blood was collected in tubes contammg 3 2% trisodium citrate
After centnfugation for 10 minutes at 2000g, plasma and white
blood cells were separated and stored at — 20°C until analysis
Matenal was collected and transported to Leiden by the study
coordmators All laboratory assessments were performed at the
Haemostasis and Thrombosis Research Centre of the Academic
Hospital Leiden High molecular weight DNA was isolated from
the white blood cell fraction by Standard methods The presence of
mutations in ti\e factor Fgene (1691, G—»A) and the prothrombm
gene (20 210, G—»A) was determmed äs previously descnbed58
Other coagulation assays were done accordmg to estabhshed
procedures protem C activity and antithrombin activity were
measured by Coamate (Chromogenix, Molndal, Sweden) on an
ACL-200 (Instrumentation Laboratory, Milan, Italy), total protem
S antigen by a polyclonal enzyme-hnked immunosorbent assay,
factor II and factor X antigen by immunoelectrophoresis, and factor
V activity by a one-stage clottmg assay on an Electra 1000C
coagulometer (MLA, Pleasantville, New York) In view of poten-
tial liver failure and anticoagulant treatment of patients with BCS
and PVT, the presence of hereditary deficiencies of protem C,
protem S, and antithrombin could only be estimated by modified
cntena äs compared to controls For controls the cntena for
diagnosis of protem deficiencies were plasma levels under the
lower limit of normal, combmed with normal factor II and
prothrombm time values 13 Patients with BCS and PVT who
satisfied these protem deficiency cntena and those with a ratio of
protem C antigen, protem S antigen, or antithrombin value to
(factor II + factor X)/2 below Ο 714 were selected for mdividual
evaluation of the presence of hereditary protem deficiencies by 2
hemostasis physicians (F R R and F J M v d M) These mvestiga-
tors, who were not involved in patient management and were
unaware of the hepatologic diagnosis, based their decision on the
results of protem C, protem S, and antithrombin testing in relation
to the patient's use of anticoagulants, the use of oral contraceptives,
and the degree of liver failure äs indicated by results of a panel of
coagulation tests (protem C, protem S, antithrombin, fibnnogen,
prothrombm time, partial thromboplastm time, factor II, factor V,
and factor X) A clear isolated deficiency of either coagulation
Inhibitor m companson to other coagulation tests was considered
äs an inhented deficiency In all cases, the presence of myeloprohf-
erative disease was confirmed by bone marrow exammation Latent
pnmary myeloprohferative disorder, äs diagnosed by erythroid
colony formation, was not tested m all patients and was not
considered to be a myeloprohferative disease Six BCS patients and
4 PVT patients had undergone liver transplantation before the date
of blood samphng For 7 of these 10 patients plasma taken before
liver transplantation could be obtamed and mvestigated for protem
C, protem S, and antithrombin deficiency Separate analysis of the
pretransplantation samples did not alter the decision on inhented
deficiency of these coagulation Inhibitors The frequencies of factor
V Leiden mutation, prothrombm mutation, and deficiency of
protem C, protem S, and antithrombin among cases and controls
were compared by simple cross-tabulation Patients who, except
for these mvestigated inhented thrombogemc conditions, did not
exhibit nsk factors for thrombosis were referred to äs idiopathic
cases The relative nsks of BCS or PVT among individuals with
thrombogemc conditions were estimated äs the odds ratio (OR) and
the 95% confidence interval (CI) accordmg to Woolf15
Results
Charactenstics of patients and controls are shown m Table l
Myeloprohferative disease was present in 12 (28%) BCS patients
and 16 (17%) PVT patients Thirty-two (74%) BCS patients and 24
(26%) PVT patients were treated with coumann derivatives This
difference may be attnbutable not only to the lack of evidence that
Table 1 Characteristlcs of patients with Budd-Chiari syndrome (BCS) and
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PNH mdicates paroxysmal nocturnal hemoglobmuna NA not available
*Median (ränge)
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Table 2 Differences in prevalences of factor V Leiden mutation, prothrombln
gene mutation, protein C deficiency, proteln S deficlency, and antithrombln
deficiency In patlents wlth Budd-Chlarl syndrome (BCS) and Controls
Table 4 Prevalence of acquired and inherited rlsk factors for Budd-Chiari
syndrome (BCS) and portal veln thrombosis (PVT)
BCS (%) Controls (%)
n = 43 n = 474 OR 95% Cl
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CI mdicates confidence mterval OR odds ratio
anticoagulation is beneficial in PVT but also to the predommance
of vanceal bleedmg in PVT patients (36%) compared to BCS
patients (7%)
Among the 43 BCS patients factor V Leiden mutation (n = 11,
25 6%, OR 11 3, 95% CI 4 8-26 5), hereditary protein C deficiency
(n = 4, 9 3%, OR 6 8, 95% CI l 9-24 4) and prothrombm gene
mutation (n = 2, 47%, OR 2 l, 95% CI 04-96) were more
prevalent than in controls (Table 2) In particular, factor V Leiden
mutation and protein C deficiency were predommant nsk factors
for BCS One patient exhibited homozygous camership for factor
V Leiden mutation, the combmed presence of factor V Leiden
mutation and hereditary protein C deficiency was found m 2
patients Protein S deficiency and antithrombln deficiency could
not be demonstrated for any of the BCS patients Among the 19
patients with idiopathic BCS, factor V Leiden mutation was found
m 7 (36 8%, OR 19 l, 95% CI 6 5-56 0) protein C deficiency m 2
(10 5%, OR 7 8, 95% CI l 5-40 6), and prothrombm gene mutation
in none
Among the 92 PVT patients, factor V Leiden mutation was
observed in 7 patients (7 6%, OR 2 7, 95% CI l 1-6 9), hereditary
protein C deficiency m 6 patients (6 5%, OR 4 6, 95% CI l 5-14 1),
and prothrombln gene mutation m 3 patients (3 2%, OR l 4, 95%
CI 0 4-5 2) (Table 3) Although less pronounced than m the BCS
group, the relative nsk of PVT was mcreased in the presence of
these thrombogenic factors In one patient with pnmary bihary
cirrhosis factor V Leiden mutation and protein C deficiency were
present simultaneously The prevalence of both protein S defi-
ciency (2 2%, OR 0 9, 95% CI 0 2-4 3) and antithrombln defi-
ciency (l 1%, OR 0 6, 95% CI 0 1-4 5) was low, bemg comparable
to that found for controls In the group of 21 patients with
idiopathic PVT factor V Leiden mutation was observed in 3
(14 2%, OR 5 5,95% CI l 4-20 7), prothrombm gene mutation m l
(4 8%, OR 2 l, 95% CI 0 3-17 1), and protein C deficiency m none
Use of oral contraceptives was an important acquired nsk factor
for BCS and PVT Among women in the age group of 15 to 49
years, oral contraceptives had been used at the time of diagnosis in
12 of 20 patients (60 0%, OR 2 4,95% CI 0 9-6 2) with BCS and m















BCS Inherited nsk factor factor V Leiden mutation n = 11 prothrombln gene
mutation n = 2 protein C deficiency n = 4 Acquired nsk factor oral contraceptives
n = 12 myeloproliferative disease n = 12 lupus anticoagulant n = 2 mflammatory
bowel disease n = 2 Wer abscess n = 1
PVT Inhented nsk factor factor V Leiden mutation n = 7 prothrombln gene
mutation n = 3 protein C deficiency n = 6 protein S deficiency n = 2 antithrombln
deficiency n = 1 Acquired nsk factor oral contraceptives n = 12 myeloproliferative
disease n = 16 cirrhosis n = 16 abdominal surgery n = 28 pancreatitis n = 10
umbilical vein infection n = 6 mflammatory bowel disease n = 4 liver abscess n = 4
abdominal trauma n = 2 paroxysmal noctumal hemoglobmuna n = 2 pregnancy n =
2 nodular regenerative hyperplasia n = 2 portal sclerosis n = 1 hepatocellular
carcmoma n = 1 semmoma n = 1
compared to 65 of 169 (38%) controls Concurrence of inhented
thrombogenic factors (le, factor V Leiden mutation, prothrombm
gene mutation, protein C deficiency, protein S deficiency, and
antithrombln deficiency) and acquired prothrombotic states for
BCS and PVT is shown m Table 4 For 11 of the 43 BCS patients
(26%) and 15 of the 92 PVT patients (16%) no nsk factors for
thrombosis could be demonstrated At least one of the inhented
prothrombotic nsk factors was present in 14 patients with BCS
(32 5%, OR 3 9,95% CI l 9-7 9) and 17 patients with PVT (18 5%,
OR l 8, 95% CI l 0-3 3) Coexistence of acquired and inhented
nsk factors was found for 6 (14%) ofthose with BCS and 13 (14%)
with PVT Analysis of all thrombogenic nsk factors, irrespective of
whether they were acquired or inherited, revealed 11 (26%)
patients with BCS and 34 (37%) patients with PVT who had more
than one nsk factor (Table 5) Three BCS patients and 12 PVT
patients exhibited 3 or more factors considered to be a nsk
for development of thrombosis in hepatic and portal veins,
respectively
Discussion
This study shows a high prevalence of factor V Leiden mutation
and hereditary protein C deficiency in patients with BCS and PVT,
mdicatmg that mdividuals with these thrombogenic conditions
have an mcreased relative nsk for both mamfestations of thrombo-
sis The prevalence of the prothrombm gene mutation was less than
5% for BCS and PVT, and mdividuals with this mutation only had
an mcreased relative nsk for BCS and PVT, which was not
significant In general, the prevalence of the mvestigated hereditary
Table 3 Differences In prevalences of factor V Leiden mutation, prothrombln
gene mutation, protein C deficiency, protein S deficiency, and antithrombln
deficiency In patients wlth portal veln thrombosis (PVT) and controls































Table S Prevalence of combined rlsk factors (acquired and Inherited) among
patients wlth Budd-Chlarl syndrome (BCS) and portal vein thrombosis (PVT)




















CI mdicates confidence mterval OR oddsratio *Risk factors äs shown
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risk factors for thrombosis was especially high among patients with
idiopathic BCS and PVT.
Mahmoud and associates, who investigated 30 BCS patients
and 32 PVT patients, reported that factor V Leiden mutation was an
important factor in the pathogenesis of BCS but not of PVT.7 The
present study, which included 92 PVT patients and therefore had
more statistical power, demonstrates that factor V Leiden mutation
is also a risk factor for PVT. Chamouard and colleagues recently
found the prothrombin gene mutation in 4 of 10 patients with PVT.9
Although they investigated a subgroup of patients with idiopathic
PVT, the importance of the prothrombin gene mutation in the
etiology of PVT could well be overestimated in that study due to
the limited number of patients included. Large studies on venous
thromboembolisms did not show a mutation frequency of more
than 6.2%, and on pathophysiologic grounds there is no reason to
believe patients with the prothrombin gene mutation would exhibit
an additional risk for PVT.8
As previously documented for patients with deep venous
thrombosis,13 the prevalences of hereditary protein S deficiency
and antithrombin deficiency were low in both BCS and PVT
patients, and no differences with controls were observed. In view of
the low prevalences of these thrombogenic states äs well äs the
investigated diseases, we cannot exclude the association of protein
S or antithrombin deficiency with BCS and PVT, äs was suggested
in several case reports.12·16·17 Although the higher prevalence of
protein S deficiency in our control group äs compared to other
estimates would not suggest so, the use of total protein S values
instead of free protein S could have led to an underestimation of the
prevalence of inherited protein S deficiency in our study.13·18 In any
case, our results indicate that inherited defects of both protein S and
antithrombin are probably not major predisposing factors in the
pathogenesis of BCS and PVT.
At least one of the inherited prothrombotic risk factors investi-
gated (factor V Leiden mutation, prothrombin gene mutation, and
protein C, protein S, or antithrombin deficiency) was present in
approximately one third of the BCS population and in one fifth of
the PVT population. The fact that the significance of these
prothrombotic abnormalities was more pronounced in BCS than in
PVT can be explained by the heterogeneous etiology of PVT in
which many focal factors, such äs abdominal surgery, pancreatitis,
and preexistent cirrhosis, appear to be of importance.
The diagnosis of inherited deficiencies in protein C, protein S,
and antithrombin in patients with BCS and PVT is difficult and
should be interpreted äs estimates primarily because acquired
deficiencies can develop in the event of liver failure, acute
thrombosis, and anticoagulant therapy. To minimize the number of
incorrectly diagnosed inherited deficiencies we decided to (1)
evaluate the levels of protein C, protein S, and antithrombin in
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